Abilify Gambling Lawsuits May Settle After Judge’s Order

Fact-Checked

Editors carefully fact-check all Drugwatch content for accuracy and quality.

Drugwatch has a stringent fact-checking process. It starts with our strict sourcing guidelines.

We only gather information from credible sources. This includes peer-reviewed medical journals, reputable media outlets, government reports, court records and interviews with qualified experts.

Judge signing order

Hundreds of lawsuits filed by people who say the antipsychotic Abilify made them gamble compulsively may settle in the next few months.

A federal judge overseeing multidistrict litigation issued an order May 2 giving the parties until Sept. 1 to finalize a framework for a global settlement.

Multidistrict litigation (MDL) is how the federal courts manage large numbers of cases filed around the country that involve similar questions of fact.

In this case, there are more than 800 pending federal lawsuits filed by people who say Abilify caused them to gamble compulsively.

There are a total of more than 900 state and federal cases filed in the U.S., with more cases pending in Canada, according to a filing with the Securities and Exchange Commission by Bristol-Myers Squibb.

Judge’s Order Issued After Settlements

The order comes days after three cases that were scheduled for trial reached their own individual settlements that involved undisclosed amounts of money being paid to the plaintiffs.

Did you suffer from compulsive behavior after Abilify use? Get a Free Case Review

The three cases that settled were to serve as bellwethers. These are the early trials in an MDL that are expected to guide parties in settlement negotiations by allowing them to see how various issues will be determined and how juries will rule.

Chief U.S. District Judge M. Casey Rodgers is managing the Abilify MLD in Pensacola, Fla.

Rogers issued an order on April 28 announcing that the three bellwether cases had settled. Those cases involved plaintiffs Fanny Lyons, Jennifer Lilly and David Viechec.

Lyons’ trial had been slated to begin June 19. The last trial, Lilly’s, was to start on Aug. 27.

Abilify Linked to Gambling, Other Behaviors

The defendants in the cases are Japanese drugmaker Otsuka and Bristol-Myers Squibb, which marketed the drug in the U.S. until 2013.

Abilify was introduced in 2002, and by 2013, it brought in nearly $8 billion a year in sales.

It is prescribed to treat conditions including bipolar disorder, schizophrenia and major depression. Doctors also prescribe it off-label for anxiety disorders, post-traumatic stress disorder and dementia, among other conditions.

Abilify’s severe side effects include compulsive gambling, sex and shopping.

  •  
  •  
  •  

Did you find Drugwatch helpful?

4 Cited Research Articles

  1. U.S. District Court for the Northern District of Florida, Pensacola Division. (2018, April 28). In Re Abilify (Aripiprazol) Products Liability Litigation. Order. Retrieved: http://www.flnd.uscourts.gov/sites/default/files/mdl9234/876%20-%20Order%2C%20Settlement%20of%20First%20Trial%20Pool%20Cases.pdf
  2. U.S. District Court for the Northern District of Florida, Pensacola Division. (2018, May 2). In Re Abilify (Aripiprazol) Products Liability Litigation. Global Settlement Order No. 1. Retrieved: http://www.flnd.uscourts.gov/sites/default/files/mdl9234/881%20-%20Global%20Settlement%20Order%20No.%201.pdf
  3. United States Securities and Exchange Commission. (2018, April 26). Form 10-Q. Bristol-Myers Squibb Company. Retrieved http://d18rn0p25nwr6d.cloudfront.net/CIK-0000014272/7e8fa63d-f293-4f50-a6a0-c73b52cdeaf1.pdf
  4. Judicial Panel on Multidistrict Litigation. (2018, April 16). MDL Statistics Report – Distribution of Pending MDL Dockets by Actions Pending. Retrieved http://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_Actions_Pending-April-16-2018.pdf
View All Sources
Call to speak with a legal expert
Who Am I Calling?

Calling this number connects you with Wilson and Peterson, LLP or one of its trusted legal partners. A law firm representative will review your case for free.

Wilson and Peterson, LLP funds Drugwatch because it supports the organization’s mission to keep people safe from dangerous drugs and medical devices.

(855) 715-9320

To contact Drugwatch Managing Editor Kevin Connolly, call (855) 839-9780.